Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ

$560.11

-$11.33 (1.98%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$552.75$573.67

Open $571.84

52 Week Range

$265.00$605.00

Previous Close $571.44

Market Cap12.42B

Volume164.43K

Avg Volume345.11K

P/E (TTM)-44.12

EPS (TTM)$-12.69

Dividend / YieldN/A

Dividend StreakN/A

Latest Press Releases for Madrigal Pharmaceuticals, Inc.

DEC152025

Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Source: GlobeNewsWire•14h ago

CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST....

DEC42025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•11 days ago

CONSHOHOCKEN, Pa., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that ...

NOV202025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•25 days ago

CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that ...

NOV172025

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

Source: GlobeNewsWire•28 days ago

CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:...

NOV102025

Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis

Source: GlobeNewsWire•35 days ago

Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved disease-specific quality of life mea...

NOV62025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•39 days ago

CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that ...

NOV42025

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates

Source: GlobeNewsWire•41 days ago

Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent f...

OCT282025

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Source: GlobeNewsWire•48 days ago

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of distinction examines the impact of Rezdiffra interrup...

OCT222025

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Source: GlobeNewsWire•54 days ago

CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that...

OCT212025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Source: GlobeNewsWire•55 days ago

CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that ...